Patents by Inventor Robert Hallas

Robert Hallas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060040239
    Abstract: A driving simulator. The driving simulator may include a processor; a display connectable to the processor; a plurality of input devices, such as a steering wheel, a brake pedal, and an accelerator pedal, where each of the plurality of input devices is connectable to the processor; and a computer-readable medium.
    Type: Application
    Filed: August 2, 2004
    Publication date: February 23, 2006
    Applicant: J. J. Keller & Associates, Inc.
    Inventors: Robert Cummins, John Garvey, Robert Halla, Keith Keller, Tim Miller, Doraivelu Palanivelu, Sukhdev Tur, Steven Velpel, Jeff Weber, Joel Williams
  • Patent number: 6274715
    Abstract: Compounds, or pharmaceutically acceptable salts and esters thereof, of the formula: wherein A, B, D and E, R1, R2, and Z are specifically defined, having antibacterial activity, pharmaceutical compositions containing said compounds, treatment of bacterial infections with such compositions, and processes for the preparation of the compounds.
    Type: Grant
    Filed: January 7, 1997
    Date of Patent: August 14, 2001
    Assignee: Abbott Laboratories
    Inventors: Yat Sun Or, Ly Tam Phan, Daniel T. Chu, Kenneth P. Spina, Robert Hallas, Richard L. Elliott, Michael Tufano
  • Patent number: 5624924
    Abstract: Quinobenzothiazine derivatives of the formula ##STR1## as well as the pharmaceutically acceptable salts, esters, amides and prodrugs thereof are disclosed, wherein R.sup.1 is hydrogen or acarboxy-protecting group, R.sup.2 and R.sup.3 are substitutents, A is oxygen, sulfur, or carbon, Z is a halogen or a nitrogen-containing group, X is hydrogen, halogen or alkyl, and W is hydrogen, alkyl, amino or halogen. The compounds have potent antineoplastic activity.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: April 29, 1997
    Assignee: Abbott Laboratories
    Inventors: Daniel T. Chu, Jacob J. Plattner, Robert Hallas
  • Patent number: 5318965
    Abstract: Quinobenzoxazine, derivatives of the formula ##STR1## as well as the pharmaceutically acceptable salts, esters, amides and prodrugs thereof are disclosed, wherein R.sup.1 is hydrogen or a carboxy-protecting group, R.sup.2 and R.sup.3 are substitutents, A is oxygen, Z is a halogen or a nitrogen-containing group, X is hydrogen, halogen or alkyl, and W is hydrogen, alkyl, amino or halogen. The compounds have potent antineoplastic activity.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: June 7, 1994
    Assignee: Abbott Laboratories
    Inventors: Daniel T. Chu, Jacob J. Plattner, Robert Hallas
  • Patent number: 5057523
    Abstract: 7-(3-A-amino-1-pyrrolidinyl) substituted naphthyridine and quinoline compounds wherein A is a solubilizing group selected from an amino acid residue or polypeptide chain.
    Type: Grant
    Filed: December 15, 1989
    Date of Patent: October 15, 1991
    Assignee: Abbott Laboratories
    Inventors: Daniel T. Chu, Robert Hallas
  • Patent number: 5057520
    Abstract: 7-(3-A-amino-1-pyrrolidinyl) substituted naphthyridine and quinoline compounds wherein A is a solubilizing group selected from an amino acid residue or polypeptide chain.
    Type: Grant
    Filed: September 1, 1989
    Date of Patent: October 15, 1991
    Assignee: Abbott Laboratories
    Inventors: Daniel T. Chu, Robert Hallas
  • Patent number: 4431799
    Abstract: Described is a method for the preparation of 6'-modified fortimicin compounds including 6'-epi fortimicin by converting 1,2-di-N-protected fortimicin B into 4,6'-di-N-substituted alkoxycarbonyl-1,2'-di-N-protected fortimicin B which is further converted to 1,2'-di-substituted fortimicin B-4,5-carbamate, a compound whose substitution pattern is particularly suited to modification at the 6'-amino group and novel compounds thereof.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: February 14, 1984
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Robert Hallas, Jerry R. Martin
  • Patent number: 4427662
    Abstract: Disclosed herein are fortimicin derivatives represented by the formula: ##STR1## wherein R is hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, loweracyl, aminoloweracyl, diaminoloweracyl, hydroxyloweracyl, N-loweralkylaminoloweracyl, N,N-diloweralkylaminoloweracyl, or aminohydroxyloweracyl, and the pharmaceutically acceptable salts thereof. Also disclosed are intermediates useful in the preparation of these compounds and compositions of these compounds together with a pharmaceutically acceptable carrier and/or diluent.
    Type: Grant
    Filed: April 9, 1982
    Date of Patent: January 24, 1984
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Robert Hallas, Leslie A. Freiberg, David J. Bacino
  • Patent number: 4331804
    Abstract: What is described is 2-epi-fortimicin A, 2-epi-fortimicin B or a 2-epi-fortimicin B derivative represented by the formula: ##STR1## wherein R.sub.1 is hydrogen or loweralkyl; R.sub.2 is hydrogen or hydroxy; R.sub.3 is methyl or hydrogen; and R.sub.4 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoalkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, acyl of the formula ##STR2## wherein R.sub.5 is loweralkyl, aminoacyl, diaminoacyl, hydroxyacyl, N-loweralkylaminoacyl, N,N-diloweralkylaminoacyl, hydroxy-substituted aminoacyl or an amino acid residue other than those defined above and the pharmaceutically acceptable salts thereof useful in the treatment of infections.
    Type: Grant
    Filed: September 26, 1979
    Date of Patent: May 25, 1982
    Assignee: Abbott Laboratories
    Inventors: John S. Tadanier, Robert Hallas, Jerry R. Martin
  • Patent number: 4063014
    Abstract: A 4"-O-sulfonyl erythromycin derivative of the following structural formula: ##STR1## where R is selected from the group consisting of oxygen, oxime, and substituted oxime, R.sub.1 is hydrogen or hydroxy and R.sub.2 is selected from the group consisting of phthalimide, substituted amides, benzamides, substituted benzamides, sulfonamides, substituted sulfonamides, amines, substituted amines, phenylurea, substituted phenylurea, phenylthiourea, substituted phenylthiourea, thiophenol and substituted thiophenol, phenoxides and substituted phenoxides and R.sub.3 is hydrogen or methyl. The present sulfonyl derivatives of erythromycin A, B and C are useful as antibiotics.
    Type: Grant
    Filed: June 12, 1975
    Date of Patent: December 13, 1977
    Assignee: Abbott Laboratories
    Inventors: Robert Hallas, Jerry Roy Martin, John Soloman Tadanier